cyclo(arginyl- glycyl- aspartyl- phenylalanyl- valyl)

an antagonist of vitronectin receptor-type integrins; structure given in first source

Also Known As:

EMD 66203; EMD-66203; H2574 peptide; c(RGDfV); cyclic Arg-Gly-Asp-D-Phe-Val; cyclic RGD(D)FV; cyclic RGDFV; cyclic arginyl-glycyl-aspartyl-phenylalanyl-valine; cyclic(Arg-Gly-Asp-D-Phe-Val); cyclo(Arg-Gly-Asp-D-Phe-Val); cyclo(RGDfV)

Networked: 10 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Matchett, Gerald: 2 articles (12/2006 - 07/2006)
2.	Ohkuma, Hiroki: 2 articles (12/2006 - 07/2006)
3.	Shimamura, Norihito: 2 articles (12/2006 - 07/2006)
4.	Zhang, John: 2 articles (12/2006 - 07/2006)
5.	Chatterjee, S: 2 articles (10/2001 - 01/2000)
6.	Matsumura, A: 2 articles (10/2001 - 01/2000)
7.	Chingle, Ramesh: 1 article (01/2017)
8.	Lubell, William D: 1 article (01/2017)
9.	Proulx, Caroline: 1 article (01/2017)
10.	Kong, Pei-Yan: 1 article (11/2016)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2004 - "In the M21/mouse model, statistically significant inhibition of tumor growth was observed for mice treated with IA-DCLs, whereas controls including saline, DCLs lacking IA, and cyclo(RGDfV) were ineffective. " 11/01/2016 - "c(RGDfV) disrupted the adhesion and migration between the tumor cells and the matrix, induced the leukemia cells to leave the protective microenvironment and increased their sensitivity to cell cycle-dependent agents (P<0.05). " 01/01/2014 - "The uptake of [⁶⁸Ga]NOTA-RGD into tumor was fully inhibited by c(RGDfV), known to bind specifically to α(v)β₃ integrin, confirming the specificity of the tumor uptake in vivo. " 01/01/2017 - "The synthesis of cyclic azapeptide derivatives was used to make an aza scan to study the conformation-activity relationships of the anticancer agent cilengitide, cyclo(RGDf-N(Me)V), and its parent counterpart cyclo(RGDfV), which exhibit potency against human tumor metastasis and tumor-induced angiogenesis. "
2.	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 07/01/2009 - "In this study, male severe combined immunodeficiency (SCID) mice were injected with colon cancer cells in the subcutis and then treated with Fumagillin and Cyclo (Arg-Gly-Asp-D-Phe-Val), an integrin alphavbeta(3) antagonist. "
3.	Neoplasm Metastasis (Metastasis) 01/01/2017 - "The synthesis of cyclic azapeptide derivatives was used to make an aza scan to study the conformation-activity relationships of the anticancer agent cilengitide, cyclo(RGDf-N(Me)V), and its parent counterpart cyclo(RGDfV), which exhibit potency against human tumor metastasis and tumor-induced angiogenesis. "
4.	Colonic Neoplasms (Colon Cancer) 07/01/2009 - "In this study, male severe combined immunodeficiency (SCID) mice were injected with colon cancer cells in the subcutis and then treated with Fumagillin and Cyclo (Arg-Gly-Asp-D-Phe-Val), an integrin alphavbeta(3) antagonist. "
5.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/01/2006 - "We studied selective inhibition of integrin alphavbeta3 with cyclo [Arg-Gly-Asp-D-Phe-Val] (cRGDfV) in the rat middle cerebral artery occlusion model (MCAO). " 12/01/2006 - "We tested the effect of postischemic treatment of cyclo-RGDfV (cRGDfV), a selective inhibitor of integrin alphavbeta3, in the middle cerebral artery occlusion (MCAO) model of ischemic stroke in rats. "

Related Drugs and Biologics

1.	Integrins
2.	Antineoplastic Agents (Antineoplastics)
3.	Cilengitide
4.	fumagillin
5.	Integrin alphaVbeta3
6.	Peptides (Polypeptides)
7.	Polystyrenes (Polystyrene)
8.	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)
9.	arginyl-glycyl-aspartic acid
10.	arginyl-glycyl-aspartyl-serine

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)